[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Coronavirus Disease 2019 (COVID-19) Impact on Novavax Inc.

December 2020 | 29 pages | ID: CB0580A24331EN
GlobalData

US$ 495.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Coronavirus Disease 2019 (COVID-19) Impact on Novavax Inc.

SUMMARY

Novavax is a late-stage clinical biotechnology company with a recombinant subunit innovative vaccine platform and an adjuvant platform to develop prophylactic vaccines against infectious diseases.

SCOPE
  • This 29-page PowerPoint based report gives an important expert analysis on how COVID-19 will affect Novavax. Findings are based on the industry‚Äôs most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
REASONS TO BUY
  • An overview of how Novavax Inc. will be affected by the COVID-19 pandemic.
1 EXECUTIVE SUMMARY

2 COMPANY OVERVIEW

3 REGIONAL ANALYSIS

4 REACTION TO COVID-19

5 KEY FINDINGS

6 APPENDIX

COMPANIES MENTIONED

Novavax Inc.


More Publications